KLK3 and ovarian carcinoma: However, as already found with CA-125 in ovarian cancers, this two time point-based kinetic strategy is largely impacted by the high inter- and intra-individual variability of sparse PSA concentrations measured with different assays, far from the actual dynamics of serum marker kinetics, thereby limiting the comparability in different patient populations than those assessed initially [24].